Literature DB >> 7252154

Purification and radiolabeling of human C1q.

A J Tenner, P H Lesavre, N R Cooper.   

Abstract

A new procedure for isolating human C1q from serum or plasma is described. The method, that is highly selective, rapid and involves minimal handling, yields fully active, immunoglobulin-free unaggregated C1q. Several different methods of radiolabeling C1q are compared. These include two methods selective for tyrosine residues, two that label lysine residues, and a method that labels sialic acid residues. The effect of each of the labeling procedures on C1q hemolytic activity was assessed. Also appraised for each method was the ability of the labeled molecules to bind to antibody sensitized cells and to interact with C1r and C1s to form C1. The distribution of each of the radiolabels among the three polypeptide chains of C1q and between the collagenous and globular regions of C1q was determined. Methods were identified that selectively labeled the globular portion of either the A or C polypeptide chain of the C1q molecule without loss of functional activity. Another of the methods labeled all three polypeptide chains relatively uniformly without significant loss of activity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7252154

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  91 in total

1.  Regulation of complement by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis.

Authors:  Kaisa E Happonen; Tore Saxne; Anders Aspberg; Matthias Mörgelin; Dick Heinegård; Anna M Blom
Journal:  Arthritis Rheum       Date:  2010-12

2.  Complement component C1q enhances invasion of human mononuclear phagocytes and fibroblasts by Trypanosoma cruzi trypomastigotes.

Authors:  M T Rimoldi; A J Tenner; D A Bobak; K A Joiner
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

3.  Antibodies against C1q in anti-glomerular basement membrane nephritis.

Authors:  I E Coremans; M R Daha; E A van der Voort; Y Muizert; C Halma; F C Breedveld
Journal:  Clin Exp Immunol       Date:  1992-02       Impact factor: 4.330

4.  Development of a humanized C1q A chain knock-in mouse: assessment of antibody independent beta-amyloid induced complement activation.

Authors:  Ming Li; Rahasson R Ager; Deborah A Fraser; Natalia O Tjokro; Andrea J Tenner
Journal:  Mol Immunol       Date:  2008-04-08       Impact factor: 4.407

5.  Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation.

Authors:  A E Ahmed; J Veitch; K Whaley
Journal:  Immunology       Date:  1990-06       Impact factor: 7.397

6.  Study of the interaction between the antitumour protein alpha-sarcin and phospholipid vesicles.

Authors:  M Gasset; A Martinez del Pozo; M Oñaderra; J G Gavilanes
Journal:  Biochem J       Date:  1989-03-01       Impact factor: 3.857

7.  Activation of the alternative and classical complement pathways by Entamoeba histolytica.

Authors:  J Calderon; R D Schreiber
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

8.  Murine low-density lipoprotein receptor-related protein 1 (LRP) is required for phagocytosis of targets bearing LRP ligands but is not required for C1q-triggered enhancement of phagocytosis.

Authors:  Anna P Lillis; Mallary C Greenlee; Irina Mikhailenko; Salvatore V Pizzo; Andrea J Tenner; Dudley K Strickland; Suzanne S Bohlson
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

9.  Antibody-independent interactions of fibronectin, C1q, and human neutrophils with Treponema pallidum.

Authors:  R E Baughn
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

10.  C4b-binding Protein Protects β-Cells from Islet Amyloid Polypeptide-induced Cytotoxicity.

Authors:  Jonatan Sjölander; Elin Byman; Klaudia Kulak; Sara C Nilsson; Enming Zhang; Ulrika Krus; Gunilla T Westermark; Petter Storm; Ben C King; Erik Renström; Anna M Blom
Journal:  J Biol Chem       Date:  2016-08-26       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.